Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.

Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX.

J Pharmacol Exp Ther. 2009 Dec;331(3):1014-24. doi: 10.1124/jpet.109.160028. Epub 2009 Sep 9.

2.

Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.

Albuquerque EX, Pereira EF, Aracava Y, Fawcett WP, Oliveira M, Randall WR, Hamilton TA, Kan RK, Romano JA Jr, Adler M.

Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13220-5. Epub 2006 Aug 16.

3.

Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning.

Pereira EF, Aracava Y, Alkondon M, Akkerman M, Merchenthaler I, Albuquerque EX.

J Mol Neurosci. 2010 Jan;40(1-2):196-203. doi: 10.1007/s12031-009-9234-3. Epub 2009 Aug 19.

PMID:
19690988
4.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

5.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

6.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
7.

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Health Technol Assess. 2001;5(1):1-137. Review.

8.

[+]-Huperzine A protects against soman toxicity in guinea pigs.

Wang Y, Wei Y, Oguntayo S, Jensen N, Doctor BP, Nambiar MP.

Neurochem Res. 2011 Dec;36(12):2381-90. doi: 10.1007/s11064-011-0564-5. Epub 2011 Aug 7.

PMID:
21822920
9.

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.

Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.

J Manag Care Pharm. 2008 Jun;14(5):451-61.

10.

A combination of [+] and [-]-Huperzine A improves protection against soman toxicity compared to [+]-Huperzine A in guinea pigs.

Wang Y, Wei Y, Oguntayo S, Doctor BP, Nambiar MP.

Chem Biol Interact. 2013 Mar 25;203(1):120-4. doi: 10.1016/j.cbi.2012.10.016. Epub 2012 Nov 2.

PMID:
23123250
11.
12.

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J.

Dement Geriatr Cogn Disord. 2005;19(4):189-95. Epub 2005 Jan 25.

PMID:
15677866
13.

Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.

Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG.

J Pharmacol Exp Ther. 2005 Dec;315(3):1346-53. Epub 2005 Sep 6.

14.

Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus.

Alexandrova EA, Aracava Y, Pereira EF, Albuquerque EX.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1051-8. doi: 10.1124/jpet.110.167700. Epub 2010 Jun 16.

15.

Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN.

Am J Geriatr Pharmacother. 2006 Jun;4(2):154-60.

PMID:
16860262
16.

Huperzine A as a pretreatment candidate drug against nerve agent toxicity.

Grunwald J, Raveh L, Doctor BP, Ashani Y.

Life Sci. 1994;54(14):991-7.

PMID:
8139389
17.
18.

Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.

Mamczarz J, Kulkarni GS, Pereira EF, Albuquerque EX.

Neurotoxicology. 2011 Dec;32(6):785-98. doi: 10.1016/j.neuro.2011.07.001. Epub 2011 Jul 19.

PMID:
21784098
19.

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

Aguglia E, Onor ML, Saina M, Maso E.

Curr Med Res Opin. 2004 Nov;20(11):1747-52.

PMID:
15537474

Supplemental Content

Support Center